Proxisome Proliferator Activated Receptor (PPAR) Compounds and Methods of Using the Same

A method of treating bone fractures, the method comprising:

• administering induced stem cells to a mammalian patient in need thereof;
• the induced stem cells derived from incubating stem cells with a pharmaceutical composition comprising a peroxisome proliferator activated receptor (PPAR) compound and a pharmaceutically acceptable carrier, excipient, diluent or adjuvant;
• wherein the PPAR compound has a chemical structure of Formula I:
• wherein:
• X is O;
• R is CH═CHR3, R3 is a carboxylic acid;
• R1 is para-CF3 and R2 is meta-H;
• or R1 is meta-CF3 and R2 is para-H;
• and
• salts, isomers, solvates, hydrates, polymorphs and prodrugs thereof.

A method of treating osteoporosis or metabolic bone disease, the method comprising:

• administering an effective amount of a pharmaceutical composition to a human patient in need thereof;
• the pharmaceutical composition comprising a peroxisome proliferator activated receptor (PPAR) compound in an amount sufficient to prompt stem cells in the patient to contribute toward improving bone density, and a pharmaceutically acceptable carrier, excipient, diluent or adjuvant;
• wherein the PPAR compound has a chemical structure of Formula I:
• wherein:
• X is O;
• R is CH═CHR3, R3 is a carboxylic acid;
• R1 is para-CF3 and R2 is meta-H;
• or R1 is meta-CF3 and R2 is para-H;
• and
• salts, isomers, solvates, hydrates, polymorphs and prodrugs thereof.

A method of treating osteoporosis or metabolic bone disease, the method comprising administering induced stem cells to a human patient in need thereof;

• the induced stem cells derived from incubating stem cells with a pharmaceutical composition comprising a peroxisome proliferator activated receptor (PPAR) compound and a pharmaceutically acceptable carrier, excipient, diluent or adjuvant;
• wherein the PPAR compound has a chemical structure of Formula I:
• wherein
• X is O;
• R is CH═CHR3, R3 is a carboxylic acid;
• R1 is para-CF3 and R2 is meta-H;
• or R1 is meta-CF3 and R2 is para-H;
• and
• salts, isomers, solvates, hydrates, polymorphs and prodrugs thereof.

A method of inducing osteogenesis or chondrogenesis, comprising:

• treating mammalian stem cells by administering an effective amount of a peroxisome proliferator activated receptor (PPAR) compound whereby the mammalian stem cells differentiate into an osteocyte cell of osteoblast lineage, or into a chondrocyte cell of chrondroblast lineage, and a pharmaceutically acceptable carrier, excipient, diluent, or adjuvant;
• wherein the PPAR compound has a chemical structure of Formula I:
• wherein
• X is O;
• R is CH═CHR3, R3 is a carboxylic acid;
• R1 is para-CF3 and R2 is meta-H;
• or R1 is meta-CF3 and R2 is para-H;
• and
• salts, isomers, solvates, hydrates, polymorphs and prodrugs thereof.

A compound comprising a structural Formula II:

• wherein
• R is OCH2R3, CH═CHR3, or (CH2)nR3 where n is 0, 1, 2 or 3, and R3 is carboxylic acid, phosphonic acid, sulfonic acid, an acidic sulfonamide, or pharmacophoric mimics thereof;
• R1 is H, CH3 or CF3;
• R2 is H, alkyl, substituted alkyl, or halogen;
• and
• R3 is H, alkyl, substituted alkyl, or halogen;
• provided that when R is OCH2CO2H, (i) either R1 is not para-CF3 or R2 is not H, and (ii) either R1 is not meta-CH3 or R2 is not para-tert-butyl;
• and salts, isomers, stereoisomers, enantiomers, racemates, solvates, hydrates, polymorphs, and prodrugs thereof.